Jupiter Neurosciences, Inc. (JUNS)
NASDAQ: JUNS · Real-Time Price · USD
1.246
-0.004 (-0.36%)
Sep 5, 2025, 2:28 PM - Market open
Jupiter Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
43.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 233.28K | -404.76K | -63.44% |
| Dec 31, 2021 | 638.04K | -488.20K | -43.35% |
| Dec 31, 2020 | 1.13M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
JUNS News
- 17 days ago - Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador - GlobeNewsWire
- 6 weeks ago - Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science - GlobeNewsWire
- 2 months ago - Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 2 months ago - Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery - GlobeNewsWire
- 2 months ago - Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador - GlobeNewsWire
- 7 months ago - Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - GlobeNewsWire
- 7 months ago - Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial - GlobeNewsWire
- 9 months ago - Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering - GlobeNewsWire